AbTx, a new player in the French biotech market, has successfully raised €1.7 million (equivalent to approximately $2 million) in a new round of seed funding.
The company, founded in 2024, focuses its activities on creating highly precise treatments for solid tumors that have previously proven resistant to standard medical protocols.
The funds raised will be directed towards the clinical development of the patented Therano-Stick platform. The team utilizes enzymatic bioconjugation to create miniaturized antibody-drug conjugates, or 'FDCs.'
The developers consider this specific manufacturing process their unique advantage, which distinguishes their technology from the competitive biotechnology sector.
Alongside securing funding, AbTx received the prestigious i-Lab award, drawing industry attention to its oncology platform. Even with a relatively modest amount of seed capital, the team now has sufficient resources to test its fragment drug conjugates in the highly competitive antibody market.